ANI Pharmaceuticals, Inc. (ANIP)
71.23
-0.76
(-1.06%)
USD |
NASDAQ |
Sep 04, 16:00
71.20
-0.03
(-0.04%)
After-Hours: 20:00
ANI Pharmaceuticals SG&A Expense (TTM) : 324.76M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 324.76M |
| March 31, 2026 | 314.87M |
| December 31, 2025 | 317.74M |
| September 30, 2025 | 304.67M |
| June 30, 2025 | 307.09M |
| March 31, 2025 | 278.14M |
| December 31, 2024 | 249.64M |
| September 30, 2024 | 224.38M |
| June 30, 2024 | 187.31M |
| March 31, 2024 | 173.25M |
| December 31, 2023 | 161.70M |
| September 30, 2023 | 150.42M |
| June 30, 2023 | 138.50M |
| March 31, 2023 | 131.70M |
| December 31, 2022 | 124.04M |
| September 30, 2022 | 121.56M |
| June 30, 2022 | 108.66M |
| March 31, 2022 | 95.52M |
| December 31, 2021 | 84.29M |
| September 30, 2021 | 67.95M |
| June 30, 2021 | 66.50M |
| March 31, 2021 | 68.89M |
| December 31, 2020 | 64.99M |
| September 30, 2020 | 64.64M |
| June 30, 2020 | 63.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 56.24M |
| December 31, 2019 | 55.84M |
| September 30, 2019 | 55.20M |
| June 30, 2019 | 52.62M |
| March 31, 2019 | 48.39M |
| December 31, 2018 | 44.06M |
| September 30, 2018 | 39.57M |
| June 30, 2018 | 35.82M |
| March 31, 2018 | 33.24M |
| December 31, 2017 | 31.58M |
| September 30, 2017 | 30.06M |
| June 30, 2017 | 28.97M |
| March 31, 2017 | 29.22M |
| December 31, 2016 | 27.83M |
| September 30, 2016 | 25.92M |
| June 30, 2016 | 24.39M |
| March 31, 2016 | 22.31M |
| December 31, 2015 | 21.16M |
| September 30, 2015 | 20.44M |
| June 30, 2015 | 19.10M |
| March 31, 2015 | 18.98M |
| December 31, 2014 | 17.94M |
| September 30, 2014 | 25.32M |
| June 30, 2014 | 23.10M |
| March 31, 2014 | 19.19M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Viatris, Inc. | 3.981B |
| Liquidia Corp. | 192.66M |
| Elanco Animal Health, Inc. | 1.519B |
| Harmony Biosciences Holdings, Inc. | 272.47M |
| Corcept Therapeutics, Inc. | 556.47M |